

## **Annual General Meeting 2013: Tecan shareholders endorse all motions proposed by the Board of Directors**

- **Increased dividend of CHF 1.50 per share**
- **Compensation report accepted by advisory vote**
- **Christa Kreuzburg elected as new member of the Board of Directors**
- **Rolf Classon, Heinrich Fischer, Oliver Fetzer, Karen Huebscher, Gérard Vaillant and Erik Walldén re-elected for a term of one year; Board re-elected Rolf Classon as Chairman**

**Männedorf, Switzerland, April 17, 2013** – The Annual General Meeting of the Tecan Group (SIX Swiss Exchange: TECN) has today endorsed all motions proposed by the Board of Directors. The shareholders approved the Annual Report, the financial statements and the consolidated financial statements, and granted discharge to the Board of Directors and the Management Board. They also approved a higher dividend versus the previous year of CHF 1.50 per registered share. The dividend will be paid out in part from the available capital contribution reserve, and the portion of CHF 1.00 is therefore not subject to withholding tax. The payout will take place on April 24, 2013.

The compensation report, which was submitted for an advisory vote for the second time, was again accepted by shareholders.

Rolf Classon, Heinrich Fischer, Dr. Oliver Fetzer, Dr. Karen Huebscher, Gérard Vaillant and Erik Walldén were re-elected as members of the Board of Directors for a term of one year. Dr. Christa Kreuzburg was elected as a new member of the Board of Directors. Rolf Classon, Chairman of the Board of Directors, thanked Dominique F. Baly, who has stepped down from the Board of Directors, for his valuable contribution and commitment.

Rolf Classon was confirmed as Chairman of the Board.

KPMG AG, Zurich, was confirmed as statutory auditor for 2013.

### **Next date for the diary**

Tecan will publish the 2013 Interim Report on August 14, 2013.

### **About Tecan**

Tecan ([www.tecan.com](http://www.tecan.com)) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by



2

partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2012, Tecan generated sales of CHF 391 million (USD 416 million; EUR 323 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

**For further information:**

**Tecan Group**

Martin Braendle

Head of Corporate Communications & Investor Relations

Tel. +41 (0) 44 922 84 30

Fax +41 (0) 44 922 88 89

[investor@tecan.com](mailto:investor@tecan.com)

[www.tecan.com](http://www.tecan.com)